Methodology: how the compounded GLP-1 prices were collected, and what all-in means

A price table is only as good as the rules that built it. These are the rules behind the compounded price ranges, written so that anyone with a browser could reproduce the table.

Provenance

The offers were observed on September 3, 2026 by the FormBlends research team for the weekly Compounded GLP-1 Price Index published on formblends.com under a CC BY 4.0 licence and available as a machine-readable feed. This site republishes the observations as data and adds its own delivery-model grouping and commentary. FormBlends sells compounded semaglutide and tirzepatide, which makes it a competitor of every other provider in the table; see the last section for how that is handled.

The unit

U.S. dollars per 28-day supply, all-in, for a new U.S. self-pay patient paying month to month with no promo code. Twenty-eight days is used because the brand injectables come in four-dose fills and most compounded offers are quoted per four weeks. When a provider bills on another cycle the figure is converted on days: $499 per 77 days is $181.45 per 28 days, not the "$166 per month" the provider's page gets by dividing by three calendar months.

All-in

All-in means everything a new patient must pay to receive the medication for the period: the medication itself; any membership or program fee that is a condition of getting it; any mandatory consult, intake or new-patient fee, spread over months one to three; shipping; and supplies where they are charged. An optional add-on (coaching, a lab panel, a nausea medication) is not included. Where a fee is reported in forums but not on the provider's own pricing page it is not added; the notes column says so.

Two reference points

Month one is the first 28 days at the starting dose in the brand labels: 0.25 mg/week semaglutide, 2.5 mg/week tirzepatide. Month four is the fourth 28 days at the first titration step, 1 mg/week semaglutide and 5 mg/week tirzepatide, with introductory pricing expired. Providers that price by dose tier contribute the tier that contains the reference dose. Providers with one price at any dose show the same figure in both columns. Providers that publish only a starting-at figure get a month-one price and a blank month four; a blank never means zero.

Prepaid terms

The lowest headline numbers in this market are prepaid: $99 a month on a 12-month plan, $72 per 28 days on a three-month bundle with a cancellation fee. They are real prices and they are not monthly prices. They live in a separate column, prepaid minimum per 28 days, always with the term that unlocks them, and they never enter the month-to-month medians.

Three observation methods

• Direct: the price was read from the provider's own public page, as served, on the observation date.
• Manual: the provider's own page states the price but its robots.txt or terms forbid automated reading, so the figure was captured by a person and is refreshed less often.
• Secondary: the provider shows a price only after a quiz or behind a bot wall. The figure comes from a named third-party report with its date. Secondary rows are published for completeness and excluded from every median, quartile, minimum and maximum on this site.

Direct and manual rows feed the statistics. Rows that price a compounded GLP-1 without naming the molecule are shown and excluded from the molecule series.

Statistics

Median and the middle half (25th to 75th percentile, linear interpolation) are reported for a series when it has at least four eligible providers; with fewer, the raw values are shown. Delivery-model subgroups follow the same rule. All arithmetic on this site is done from the published data file; the numbers on the ranges page were recomputed from it on September 4, 2026.

Brand reference rows

Zepbound and Wegovy self-pay prices are recorded alongside for context and are never averaged with compounded offers. They are different products: FDA-approved, with a list price, a label and a manufacturer, against compounded preparations that are none of those. The comparison page is about why.

FormBlends' own rows

FormBlends appears under identical rules. On the observation date its product pages published an entry price only ($99 semaglutide, $349 tirzepatide) with no public recurring price, dose behaviour or renewal terms, so its month-four cells are blank and its required-fee cell is recorded as not published rather than as zero. Its rows are not ranked, highlighted or adjusted, and this site does not link its compounded table to a FormBlends checkout.

What the table cannot tell you

Prices are snapshots on a date, not quotes, and providers may quote differently by state, pharmacy, dose or after an intake. The table says nothing about pharmacy sourcing, licensure, prescriber model, refund terms or outcomes. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before sale. A low price is a low price, and that is all it is.

Corrections

If you represent a provider whose price has changed or is misread, or whose pricing was secondary and is now public, send the URL to hello@formblends.com. Re-observation is done against the provider's own page and the change is dated in the underlying index's changelog.